(CNI) Canadian National Railway - Overview
Stock: Rail, Intermodal, Trucking, Freight, Logistics
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.59% |
| Yield on Cost 5y | 2.66% |
| Yield CAGR 5y | 6.71% |
| Payout Consistency | 100.0% |
| Payout Ratio | 33.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.3% |
| Relative Tail Risk | -0.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -10.64 |
| Character TTM | |
|---|---|
| Beta | 0.577 |
| Beta Downside | 0.395 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.13% |
| CAGR/Max DD | -0.11 |
Description: CNI Canadian National Railway January 27, 2026
Canadian National Railway Company (NYSE:CNI) operates an integrated rail, intermodal, and trucking network across Canada and the United States, offering a full suite of transportation services-from rail haulage and custom brokerage to door-to-door logistics and specialized cargo handling. Its customer base spans automotive, coal, fertilizers, temperature-controlled goods, forest products, grain, metals, petroleum, chemicals, consumer goods, and third-party logistics providers.
Key recent metrics highlight the company’s scale and growth trajectory: FY 2023 revenue reached $23.0 billion, up 5% YoY, while the operating ratio improved to 61.9% (the lowest in a decade), reflecting higher pricing power and cost efficiencies. Intermodal volumes grew 7% year-over-year, driven by sustained demand for e-commerce and temperature-controlled shipments, and the network now spans 20,000 miles of track with 2,200 locomotives in service. Macro-level drivers include robust North-American freight demand, a rebound in grain exports from the Midwest, and continued investment in U.S. infrastructure that supports rail capacity expansions.
For a deeper, data-driven look at CN’s valuation and risk profile, the ValueRay platform provides a concise, research-ready overview.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 4.72b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.27 > 1.0 |
| NWC/Revenue: -7.07% < 20% (prev -7.96%; Δ 0.89% < -1%) |
| CFO/TA 0.12 > 3% & CFO 7.05b > Net Income 4.72b |
| Net Debt (21.46b) to EBITDA (8.82b): 2.43 < 3 |
| Current Ratio: 0.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (616.0m) vs 12m ago -2.14% < -2% |
| Gross Margin: 43.58% > 18% (prev 0.41%; Δ 4317 % > 0.5%) |
| Asset Turnover: 29.95% > 50% (prev 29.87%; Δ 0.08% > 0%) |
| Interest Coverage Ratio: 8.11 > 6 (EBITDA TTM 8.82b / Interest Expense TTM 848.8m) |
Altman Z'' 2.32
| A: -0.02 (Total Current Assets 2.47b - Total Current Liabilities 3.69b) / Total Assets 58.51b |
| B: 0.32 (Retained Earnings 18.90b / Total Assets 58.51b) |
| C: 0.12 (EBIT TTM 6.88b / Avg Total Assets 57.79b) |
| D: 0.58 (Book Value of Equity 21.29b / Total Liabilities 36.96b) |
| Altman-Z'' Score: 2.32 = BBB |
Beneish M -3.21
| DSRI: 0.84 (Receivables 1.12b/1.31b, Revenue 17.31b/17.05b) |
| GMI: 0.94 (GM 43.58% / 40.87%) |
| AQI: 1.05 (AQ_t 0.11 / AQ_t-1 0.11) |
| SGI: 1.02 (Revenue 17.31b / 17.05b) |
| TATA: -0.04 (NI 4.72b - CFO 7.05b) / TA 58.51b) |
| Beneish M-Score: -3.21 (Cap -4..+1) = AA |
What is the price of CNI shares?
Over the past week, the price has changed by +6.01%, over one month by +1.97%, over three months by +8.04% and over the past year by +1.52%.
Is CNI a buy, sell or hold?
- StrongBuy: 9
- Buy: 7
- Hold: 14
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the CNI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 109 | 7.4% |
| Analysts Target Price | 109 | 7.4% |
| ValueRay Target Price | 109.5 | 8% |
CNI Fundamental Data Overview February 09, 2026
P/E Forward = 17.4216
P/S = 3.5884
P/B = 3.9309
P/EG = 2.1294
Revenue TTM = 17.31b USD
EBIT TTM = 6.88b USD
EBITDA TTM = 8.82b USD
Long Term Debt = 20.30b USD (from longTermDebt, last quarter)
Short Term Debt = 905.3m USD (from shortTermDebt, last quarter)
Debt = 21.82b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.46b USD (from netDebt column, last quarter)
Enterprise Value = 83.56b USD (62.09b + Debt 21.82b - CCE 350.0m)
Interest Coverage Ratio = 8.11 (Ebit TTM 6.88b / Interest Expense TTM 848.8m)
EV/FCF = 24.65x (Enterprise Value 83.56b / FCF TTM 3.39b)
FCF Yield = 4.06% (FCF TTM 3.39b / Enterprise Value 83.56b)
FCF Margin = 19.59% (FCF TTM 3.39b / Revenue TTM 17.31b)
Net Margin = 27.27% (Net Income TTM 4.72b / Revenue TTM 17.31b)
Gross Margin = 43.58% ((Revenue TTM 17.31b - Cost of Revenue TTM 9.76b) / Revenue TTM)
Gross Margin QoQ = 46.30% (prev 44.90%)
Tobins Q-Ratio = 1.43 (Enterprise Value 83.56b / Total Assets 58.51b)
Interest Expense / Debt = 1.07% (Interest Expense 233.8m / Debt 21.82b)
Taxrate = 25.22% (420.7m / 1.67b)
NOPAT = 5.14b (EBIT 6.88b * (1 - 25.22%))
Current Ratio = 0.67 (Total Current Assets 2.47b / Total Current Liabilities 3.69b)
Debt / Equity = 1.01 (Debt 21.82b / totalStockholderEquity, last quarter 21.55b)
Debt / EBITDA = 2.43 (Net Debt 21.46b / EBITDA 8.82b)
Debt / FCF = 6.33 (Net Debt 21.46b / FCF TTM 3.39b)
Total Stockholder Equity = 21.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.17% (Net Income 4.72b / Total Assets 58.51b)
RoE = 21.95% (Net Income TTM 4.72b / Total Stockholder Equity 21.50b)
RoCE = 16.46% (EBIT 6.88b / Capital Employed (Equity 21.50b + L.T.Debt 20.30b))
RoIC = 12.14% (NOPAT 5.14b / Invested Capital 42.39b)
WACC = 6.16% (E(62.09b)/V(83.91b) * Re(8.04%) + D(21.82b)/V(83.91b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 8.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.47%
[DCF Debug] Terminal Value 85.03% ; FCFF base≈3.29b ; Y1≈3.22b ; Y5≈3.26b
Fair Price DCF = 112.0 (EV 89.94b - Net Debt 21.46b = Equity 68.48b / Shares 611.4m; r=6.16% [WACC]; 5y FCF grow -3.17% → 2.90% )
EPS Correlation: 27.87 | EPS CAGR: 12.16% | SUE: 0.76 | # QB: 0
Revenue Correlation: 22.57 | Revenue CAGR: 5.05% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.78 | Chg30d=-0.102 | Revisions Net=-10 | Analysts=23
EPS current Year (2026-12-31): EPS=7.87 | Chg30d=-0.300 | Revisions Net=-20 | Growth EPS=+3.1% | Growth Revenue=+1.9%
EPS next Year (2027-12-31): EPS=8.77 | Chg30d=-0.325 | Revisions Net=-14 | Growth EPS=+11.5% | Growth Revenue=+5.1%